The MD Magazine Hypertriglyceridemia condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Latest Headlines

FDA Approves PCSK9 Inhibitor
The US Food and Drug Administration on Friday approved the first cholesterol-lowering treatment in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors.
Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) project, a 4-year Centers for Medicare and Medicaid Services-sponsored demonstration project, showed that a telemedicine intervention can improve glycemic, lipid, and blood pressure control.
Friday could be a big day for cardiologists. The FDA is due to rule July 24 on what could be the first available PCSK9 inhibitor, one of a new class of cholesterol-lowering agents meant to help patients who cannot get their LDL levels low enough with statins. New York City cardiologist David Vorchheimer, MD. talks about his hopes for the new drugs, and a few concerns
Tocilizumab treated rheumatoid arthritis patients are at an increased risk for major adverse cardiovascular events, according to a study published in Arthritis & Rheumatology.
Young women who breastfeed may have a reduced risk of early subclinical atherosclerosis during midlife, compared with those who bottle feed their babies, according to research published in the August issue of Obstetrics & Gynecology.

Advanced lipid testing can be useful in predicting cardiac risk, but tests are often underutilized.
The medical world is eagerly awaiting the likely approval this summer of two new cholesterol-lowering drugs, known as PCSK9 inhibitors. But at a cost of $7,000 to $12,000 a year, they won't be for everyone.

Most Popular

$vacMongoViewPlus$ $vAR$